Internasjonale ph.d. gjesteforskere kan registreres i FS som PhD-VISIT og gis studentrettigheter, dersom deres finansiering er tilsvarende lånekassen sine satser. For oppdatert informasjon: https://www.uib.no/foransatte/130671/internasjonale-phd-gjesteforskere-med-egne-midler
We will show you how to create your educational portifolio (will be required for future academic positions), practical use of MCQ in Mitt UiB and Martin Biermann will talk about how to use e-learning platforms to promote learning. After lunch, we sum up the OSCE (objective structured clinical exam) –experiences , and we may all take part in groups creating new OSCE tasks that may be included in the exam database. Please register here. Press «continue reading» to view the program of the day.
Lunsjseminaret har som vanlig to høyaktuelle innlegg. Denne gang får vi besøk fra Norsk sender for forskningsdata som vil snakke om forskjellen mellom anonymisering og avidentifisering av forskningsdata.
Videre vil professor Nils Roar Gjerdet komme for å snakke om sluttfasen av et ph.d.-prosjekt: hvordan opprettholde momentum og hvilken rolle veileder spiller her.
Lenke til påmelding: https://www.uib.no/med/134238/veilederlunsj-phd-veiledere
Lunsjseminaret er gratis.
Prosjekt Tjenesteutvikling arrangerer POP-UP verksted i uke 11! Denne uken er vi innom de ulike fakultetene for å ha korte verksteder/kurs der du kan lære ny metodikk. Oversikt over de ulike kursene og hvor de befinner seg finner du her.
POP-UP verksted er et lavterskeltilbud for administrativt ansatte ved UiB. POP-UP verkstedene har ulike tema, varer 45 min og vil arrangeres på ulike lokasjoner i uke 11 (09.mars-13.mars). Se mer informasjon på www.uib.no/tjenesteutvikling
The Norwegian Society for Flow Cytometry (NFCF) would like to welcome you to:
· Nordic Flow Cytometry Meeting 2020 – Thursday 27th and Friday 28th of August
Expand your horizon with versatile talks by exciting international and Scandinavian speakers (see attached program). Meet the Scandinavian cytometry community and make new contacts. Discover the latest innovations at the commercial exhibition and talks. Submit an abstract and discuss your project during the poster session. For students: A poster at this international conference is eligible for 2 study points (ECTS) at all Norwegian Universities.
· Basic Flow Cytometry course – Wednesday 26th of August (optional)
The day before the meeting, a flow cytometry course will be held by the talented Dr. Mikkel S. and Dr. Charlotte C. Petersen. You can sign up for this course in addition to the meeting. For students: The course is eligible for 1 study point (ECTS) at different Norwegian Universities.
For registration and more information: www.flowcytometri.no/oslo-2020
For a list of the speakers and more information about the course topics, see the attached file: Flyer NordicFlowCytometryMeeting2020
Can you tell us a little about your work? What are your specific tasks?
I am employed in a 100% position as professor of medical virology at the Department of Clinical Science. In addition, I am a senior consultant in the microbiology department, Haukeland University Hospital. In this latter position, I have for many years been involved in the introduction and use of nucleic acid diagnostics (e.g., PCR) for the rapid and accurate detection of viral infections in patients. Clinical and laboratory work is very useful in virology teaching for medical students.
At K2, I am the group leader for the Prostate Cancer Therapy Research Group. This group has a solid molecular biological background and has researched basic regulatory and signaling mechanisms in cancer cells and virus-infected cells. Over the past few years, innovation has become a bigger role. Panels of chemical substances have been screened for effect on cancer cells, and we have discovered new chemical substances and published what for protein the drug interacts with in the cell and the mechanisms of action. Patenting is underway in collaboration with VIS and with further development in collaboration with research groups in Shanghai and the company Xennials Therapeutics in Chicago. One exciting project is cryoimmunotherapy, abbreviated CryoIT. This is a form of immunotherapy that uses the patient’s own dendritic immune cells. After parts of the cancerous tissue are killed by a freezing process with special equipment inside the patient, the immune cells are injected into the freeze-killed cancerous tissue. These dendritic cells are capable of responding to what is different in cancer cells and can then instruct the entire immune system to attack the cancer cells, including cancer cells that have spread in metastases around the body. A Phase I clinical trial has just been conducted with CryoIT for patients with metastatic prostate cancer. The results are very useful for the next generation CryoIT with start-up in 2021.
The research group has received support from the Research Council’s program NFR TREATMENT and from the Cancer Society for robust production of more potent therapeutic dendritic cells for the next generation of CryoIT. The cells will be produced in the new therapeutic cell laboratory in the Helse Bergen building on the Laboratory building floor 1M. In this work, we focus on a synergy between the pharmacological screening project and CryoIT.
What do you enjoy working on at K2?
It is research that is the major challenge and the biggest commitment, otherwise I would probably have gone in clinical direction with patient work at the hospital. The collaboration with the others in the group and colleagues and clinical teams is inspiring. It is also rewarding to be able to teach and disseminate to the students and to experience the many young talents that are going on with their education and goals. I feel that there is a good environment in the Laboratory building, but that the potential for research and innovation is still greater than what has manifested itself until now. We have a compact medical campus with a very well equipped laboratory. It is sad that so many colleagues lack project funding. In particular, the experimental research is underfunded as operating expenses are relatively high. I am extremely grateful for the great support that my research group has received from private heathens in Bergen. This support has been essential to ensure that our projects are progressing well, that new people are being hired, and that we are looking forward to exciting years where new cancer treatment is a key goal.
Here are recent publications with contributions from K2 based on last week’s search on PubMed (and optionally articles that have not been included in previous lists). This time the list includes in total 6 recent publications. The entries appear in the order they were received from NCBI. If you have publications that are not included in this or previous lists, please send the references to Oda Barth Vedøy.